Gut dysbiosis associated with hepatitis C virus infection

Takako Inoue, Jiro Nakayama, Kei Moriya, Hideto Kawaratani, Rie Momoda, Kiyoaki Ito, Etsuko Iio, Shunsuke Nojiri, Kei Fujiwara, Masashi Yoneda, Hitoshi Yoshiji, Yasuhito Tanaka

研究成果: ジャーナルへの寄稿記事

11 引用 (Scopus)

抄録

Background. Little is known about the effect of hepatitis C virus (HCV) infection on gut microbiota and the relationship between alteration of gut microbiota and chronic hepatitis C (CHC) progression. We performed a comparative study of gut microbiota composition between CHC patients and healthy individuals. Methods. Fecal samples from 166 CHC patients were compared with those from 23 healthy individuals; the gut microbiota community was analyzed using 16S ribosomal RNA gene sequencing. CHC patients were diagnosed with persistently normal serum alanine aminotransferase without evidence of liver cirrhosis (LC) (PNALT, n = 18), chronic hepatitis (CH, n = 84), LC (n = 40), and hepatocellular carcinoma in LC (n = 24). Results. Compared with healthy individuals, bacterial diversity was lower in persons with HCV infection, with a decrease in the order Clostridiales and an increase in Streptococcus and Lactobacillus. Microbiota dysbiosis already appeared in the PNALT stage with the transient increase in Bacteroides and Enterobacteriaceae. Predicted metagenomics of microbial communities showed an increase in the urease gene mainly encoded by viridans streptococci during CHC progression, consistent with a significantly higher fecal pH in CH and LC patients than in healthy individuals or those in the PNALT stage. Conclusions. HCV infection is associated with gut dysbiosis, even in patients with mild liver disease. Additionally, overgrowth of viridans streptococci can account for hyperammonemia in CH and LC. Further studies would help to propose a novel treatment strategy because the gut microbiome can be therapeutically altered, potentially reducing the complications of chronic liver disease.

元の言語英語
ページ(範囲)869-877
ページ数9
ジャーナルClinical Infectious Diseases
67
発行部数6
DOI
出版物ステータス出版済み - 1 1 2018

Fingerprint

Dysbiosis
Chronic Hepatitis C
Virus Diseases
Hepacivirus
Liver Cirrhosis
Viridans Streptococci
Liver Diseases
16S Ribosomal RNA
RNA Sequence Analysis
Hyperammonemia
Metagenomics
Bacteroides
Urease
Microbiota
Lactobacillus
Enterobacteriaceae
Chronic Hepatitis
Streptococcus
Alanine Transaminase
rRNA Genes

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

これを引用

Inoue, T., Nakayama, J., Moriya, K., Kawaratani, H., Momoda, R., Ito, K., ... Tanaka, Y. (2018). Gut dysbiosis associated with hepatitis C virus infection. Clinical Infectious Diseases, 67(6), 869-877. https://doi.org/10.1093/cid/ciy205

Gut dysbiosis associated with hepatitis C virus infection. / Inoue, Takako; Nakayama, Jiro; Moriya, Kei; Kawaratani, Hideto; Momoda, Rie; Ito, Kiyoaki; Iio, Etsuko; Nojiri, Shunsuke; Fujiwara, Kei; Yoneda, Masashi; Yoshiji, Hitoshi; Tanaka, Yasuhito.

:: Clinical Infectious Diseases, 巻 67, 番号 6, 01.01.2018, p. 869-877.

研究成果: ジャーナルへの寄稿記事

Inoue, T, Nakayama, J, Moriya, K, Kawaratani, H, Momoda, R, Ito, K, Iio, E, Nojiri, S, Fujiwara, K, Yoneda, M, Yoshiji, H & Tanaka, Y 2018, 'Gut dysbiosis associated with hepatitis C virus infection', Clinical Infectious Diseases, 巻. 67, 番号 6, pp. 869-877. https://doi.org/10.1093/cid/ciy205
Inoue T, Nakayama J, Moriya K, Kawaratani H, Momoda R, Ito K その他. Gut dysbiosis associated with hepatitis C virus infection. Clinical Infectious Diseases. 2018 1 1;67(6):869-877. https://doi.org/10.1093/cid/ciy205
Inoue, Takako ; Nakayama, Jiro ; Moriya, Kei ; Kawaratani, Hideto ; Momoda, Rie ; Ito, Kiyoaki ; Iio, Etsuko ; Nojiri, Shunsuke ; Fujiwara, Kei ; Yoneda, Masashi ; Yoshiji, Hitoshi ; Tanaka, Yasuhito. / Gut dysbiosis associated with hepatitis C virus infection. :: Clinical Infectious Diseases. 2018 ; 巻 67, 番号 6. pp. 869-877.
@article{c350bdc1c0204a9aa61f0262cb2c5cb3,
title = "Gut dysbiosis associated with hepatitis C virus infection",
abstract = "Background. Little is known about the effect of hepatitis C virus (HCV) infection on gut microbiota and the relationship between alteration of gut microbiota and chronic hepatitis C (CHC) progression. We performed a comparative study of gut microbiota composition between CHC patients and healthy individuals. Methods. Fecal samples from 166 CHC patients were compared with those from 23 healthy individuals; the gut microbiota community was analyzed using 16S ribosomal RNA gene sequencing. CHC patients were diagnosed with persistently normal serum alanine aminotransferase without evidence of liver cirrhosis (LC) (PNALT, n = 18), chronic hepatitis (CH, n = 84), LC (n = 40), and hepatocellular carcinoma in LC (n = 24). Results. Compared with healthy individuals, bacterial diversity was lower in persons with HCV infection, with a decrease in the order Clostridiales and an increase in Streptococcus and Lactobacillus. Microbiota dysbiosis already appeared in the PNALT stage with the transient increase in Bacteroides and Enterobacteriaceae. Predicted metagenomics of microbial communities showed an increase in the urease gene mainly encoded by viridans streptococci during CHC progression, consistent with a significantly higher fecal pH in CH and LC patients than in healthy individuals or those in the PNALT stage. Conclusions. HCV infection is associated with gut dysbiosis, even in patients with mild liver disease. Additionally, overgrowth of viridans streptococci can account for hyperammonemia in CH and LC. Further studies would help to propose a novel treatment strategy because the gut microbiome can be therapeutically altered, potentially reducing the complications of chronic liver disease.",
author = "Takako Inoue and Jiro Nakayama and Kei Moriya and Hideto Kawaratani and Rie Momoda and Kiyoaki Ito and Etsuko Iio and Shunsuke Nojiri and Kei Fujiwara and Masashi Yoneda and Hitoshi Yoshiji and Yasuhito Tanaka",
year = "2018",
month = "1",
day = "1",
doi = "10.1093/cid/ciy205",
language = "English",
volume = "67",
pages = "869--877",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Gut dysbiosis associated with hepatitis C virus infection

AU - Inoue, Takako

AU - Nakayama, Jiro

AU - Moriya, Kei

AU - Kawaratani, Hideto

AU - Momoda, Rie

AU - Ito, Kiyoaki

AU - Iio, Etsuko

AU - Nojiri, Shunsuke

AU - Fujiwara, Kei

AU - Yoneda, Masashi

AU - Yoshiji, Hitoshi

AU - Tanaka, Yasuhito

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background. Little is known about the effect of hepatitis C virus (HCV) infection on gut microbiota and the relationship between alteration of gut microbiota and chronic hepatitis C (CHC) progression. We performed a comparative study of gut microbiota composition between CHC patients and healthy individuals. Methods. Fecal samples from 166 CHC patients were compared with those from 23 healthy individuals; the gut microbiota community was analyzed using 16S ribosomal RNA gene sequencing. CHC patients were diagnosed with persistently normal serum alanine aminotransferase without evidence of liver cirrhosis (LC) (PNALT, n = 18), chronic hepatitis (CH, n = 84), LC (n = 40), and hepatocellular carcinoma in LC (n = 24). Results. Compared with healthy individuals, bacterial diversity was lower in persons with HCV infection, with a decrease in the order Clostridiales and an increase in Streptococcus and Lactobacillus. Microbiota dysbiosis already appeared in the PNALT stage with the transient increase in Bacteroides and Enterobacteriaceae. Predicted metagenomics of microbial communities showed an increase in the urease gene mainly encoded by viridans streptococci during CHC progression, consistent with a significantly higher fecal pH in CH and LC patients than in healthy individuals or those in the PNALT stage. Conclusions. HCV infection is associated with gut dysbiosis, even in patients with mild liver disease. Additionally, overgrowth of viridans streptococci can account for hyperammonemia in CH and LC. Further studies would help to propose a novel treatment strategy because the gut microbiome can be therapeutically altered, potentially reducing the complications of chronic liver disease.

AB - Background. Little is known about the effect of hepatitis C virus (HCV) infection on gut microbiota and the relationship between alteration of gut microbiota and chronic hepatitis C (CHC) progression. We performed a comparative study of gut microbiota composition between CHC patients and healthy individuals. Methods. Fecal samples from 166 CHC patients were compared with those from 23 healthy individuals; the gut microbiota community was analyzed using 16S ribosomal RNA gene sequencing. CHC patients were diagnosed with persistently normal serum alanine aminotransferase without evidence of liver cirrhosis (LC) (PNALT, n = 18), chronic hepatitis (CH, n = 84), LC (n = 40), and hepatocellular carcinoma in LC (n = 24). Results. Compared with healthy individuals, bacterial diversity was lower in persons with HCV infection, with a decrease in the order Clostridiales and an increase in Streptococcus and Lactobacillus. Microbiota dysbiosis already appeared in the PNALT stage with the transient increase in Bacteroides and Enterobacteriaceae. Predicted metagenomics of microbial communities showed an increase in the urease gene mainly encoded by viridans streptococci during CHC progression, consistent with a significantly higher fecal pH in CH and LC patients than in healthy individuals or those in the PNALT stage. Conclusions. HCV infection is associated with gut dysbiosis, even in patients with mild liver disease. Additionally, overgrowth of viridans streptococci can account for hyperammonemia in CH and LC. Further studies would help to propose a novel treatment strategy because the gut microbiome can be therapeutically altered, potentially reducing the complications of chronic liver disease.

UR - http://www.scopus.com/inward/record.url?scp=85051627565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051627565&partnerID=8YFLogxK

U2 - 10.1093/cid/ciy205

DO - 10.1093/cid/ciy205

M3 - Article

VL - 67

SP - 869

EP - 877

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -